- Conditions
- Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Interventions
- Pelabresib, Ruxolitinib, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 430 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Chandler, Arizona • La Jolla, California + 14 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Dermatomyositis, Polymyositis
- Interventions
- M5049 dose, Placebo
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 9 more
- Conditions
- Acute Coronary Syndrome
- Interventions
- dalcetrapib, Placebo
- Drug
- Lead sponsor
- DalCor Pharmaceuticals
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 6,147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 122
- States / cities
- Alexander City, Alabama • Huntsville, Alabama • Mobile, Alabama + 119 more
- Conditions
- Venous Leg Ulcer
- Interventions
- S42909 100 mg, S42909 200 mg, S42909 400 mg, S42909 800 mg, S42909 1200 mg, Placebo Oral Tablet
- Drug
- Lead sponsor
- Ilkos Therapeutic Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 14
- States / cities
- Carlsbad, California • Carmichael, California • Castro Valley, California + 10 more
- Conditions
- Nucleophosmin 1-mutated Acute Myeloid Leukemia
- Interventions
- Entospletinib, Placebo, Cytarabine, Anthracycline
- Drug
- Lead sponsor
- Kronos Bio
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 10
- States / cities
- Duarte, California • Los Angeles, California • Indianapolis, Indiana + 7 more
- Conditions
- Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS)
- Interventions
- Metyrapone 250 mg Oral Tablets, Placebo
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Atrial Fibrillation
- Interventions
- Colchicine, 0.6 mg PO BID, Matching placebo
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Diabetic Kidney Disease
- Interventions
- INV-202, Placebo
- Drug
- Lead sponsor
- Inversago Pharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 23
- States / cities
- Garden Grove, California • Pomona, California • Salinas, California + 19 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- CP-690,550, Methotrexate, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 694 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 59
- States / cities
- Huntsville, Alabama • Gilbert, Arizona • Peoria, Arizona + 48 more
- Conditions
- Resistant Hypertension
- Interventions
- Aprocitentan 12.5 mg, Aprocitentan 25 mg, Placebo
- Drug
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 730 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 41
- States / cities
- Alexander City, Alabama • Inglewood, California • Lincoln, California + 37 more
- Conditions
- Ulcerative Colitis (UC)
- Interventions
- Placebo, Upadacitinib
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 16 Years to 75 Years
- Enrollment
- 522 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 114
- States / cities
- Mobile, Alabama • Sun City, Arizona • Tempe, Arizona + 90 more
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- 744 Tablet, 744 LA Injection, Placebo Tablet, Placebo Injection
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 127 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 10
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 5 more
- Conditions
- Single Ventricle Heart Disease
- Interventions
- Udenafil, Placebo
- Drug
- Lead sponsor
- Mezzion Pharma Co. Ltd
- Industry
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Diego, California + 22 more
- Conditions
- Breast Cancer
- Interventions
- Ruxolitinib, Capecitabine, Placebo
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 80
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Sedona, Arizona + 77 more
- Conditions
- Epilepsy
- Interventions
- OPC-214870, Placebo
- Drug · Other
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Ormond Beach, Florida
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- TERN-101, Placebo
- Drug · Other
- Lead sponsor
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 31
- States / cities
- Chandler, Arizona • Tucson, Arizona • Coronado, California + 23 more
- Conditions
- Recurrent Bacterial Vaginosis
- Interventions
- Metronidazole (male partner), Placeob (male partner)
- Drug · Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years to 50 Years
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Pell City, Alabama
- Conditions
- Depressive Disorder, Anxiety
- Interventions
- JNJ-42165279, Placebo
- Drug · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 8
- States / cities
- Costa Mesa, California • Oceanside, California • Miami, Florida + 5 more
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Remibrutinib, Teriflunomide
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1,007 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 50
- States / cities
- Phoenix, Arizona • Hanford, California • Los Angeles, California + 42 more
- Conditions
- Psoriasis, Skin Diseases
- Interventions
- Orismilast modified release tablets, Placebo
- Drug
- Lead sponsor
- UNION therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 7
- States / cities
- Cromwell, Connecticut • Washington D.C., District of Columbia • Beverly, Massachusetts + 3 more
- Conditions
- Treatment Outcome
- Interventions
- Vortioxetine, Escitalopram, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 447 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 53
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 50 more
- Conditions
- Multiple Sclerosis
- Interventions
- IMU-838, Placebo matching IMU-838
- Drug
- Lead sponsor
- Immunic AG
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 8
- States / cities
- Coral Springs, Florida • Naples, Florida • Ormond Beach, Florida + 5 more
- Conditions
- Endothelial Dysfunction
- Interventions
- Climara, Placebo patch, Resveratrol, Placebo
- Drug · Dietary Supplement
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 50 Years to 70 Years · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Healthy Volunteers
- Interventions
- GSBR-1290 (Capsule/Tablet), GSBR-1290, Placebo, Placebo (Capsule/Tablet)
- Drug
- Lead sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 3
- States / cities
- Miami, Florida • Baltimore, Maryland